Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers.

Tortorici MA, Matschke K, Korth-Bradley JM, DiLea C, Lasseter KC.

Clin Pharmacol Drug Dev. 2014 Jan;3(1):51-6. doi: 10.1002/cpdd.40. Epub 2013 Jun 18.

PMID:
27128230
2.

Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.

Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH.

Clin Cancer Res. 2012 Nov 15;18(22):6364-72. doi: 10.1158/1078-0432.CCR-12-1499. Epub 2012 Sep 26.

3.

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18. doi: 10.1007/s00280-012-1854-6. Epub 2012 Mar 7.

4.

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C.

Cancer Chemother Pharmacol. 2012 Jan;69(1):281-7. doi: 10.1007/s00280-011-1754-1. Epub 2011 Oct 9.

PMID:
21984222
5.

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.

Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.

J Clin Oncol. 2010 Apr 10;28(11):e169-71; author reply e172. doi: 10.1200/JCO.2009.26.4945. Epub 2010 Mar 1. No abstract available.

PMID:
20194843
6.

Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function.

Liang E, Wong YN, Allen I, Kao R, Marino M, DiLea C.

J Clin Pharmacol. 2003 Dec;43(12):1361-9.

PMID:
14615472
7.

First-time-in-human dose selection: allometric thoughts and perspectives.

Boxenbaum H, DiLea C.

J Clin Pharmacol. 1995 Oct;35(10):957-66. Review.

PMID:
8568013
8.

Comparative kinetics of sematilide in four species.

Hinderling PH, Dilea C, Koziol T, Millington G.

Drug Metab Dispos. 1993 Jul-Aug;21(4):662-9.

PMID:
8104126
9.

The pharmacokinetics of oral isradipine in normal volunteers.

Clifton GD, Blouin RA, Dilea C, Schran HF, Hassell AE, Gonasun LM, Foster TS.

J Clin Pharmacol. 1988 Jan;28(1):36-42.

PMID:
2965165

Supplemental Content

Support Center